| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 01/19/2006 | US20060014963 2-Oxo-benzimidazolyl substituted ethanolamine derivatives and their use as beta3 agonists |
| 01/19/2006 | US20060014953 7-3-Amino-4-(2,4,5-trifluorophenyl)butanoyl]-2-(trifluoromethyl)-5,6,7,8-tetrahydro[1,2,4]triazolo[1,5- alpha ]pyrazine, hydrochloride; antidiabetic agent, non-insulin dependent diabetes; synergistic mixture with other active ingredients |
| 01/19/2006 | US20060014951 4-amino-substituted pyrimidine derivatives |
| 01/19/2006 | US20060014948 e.g 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[3-[(2-methoxyethoxy)-methoxy]-4-methylbenzyl]-4-[2-[(3R)-3-methoxymethyl-morpholino]ethyl]piperazine; treating or preventing Tachykinin-mediated diseases in humans or animals |
| 01/19/2006 | US20060014837 Use of the (1S, 2R) enantiomer of milnacipran for the preparation of a drug |
| 01/19/2006 | US20060014830 2-amino-2-oxoethyl 1-(4'-fluoro-1,1'-biphenyl-4-yl)cyclopropylmethylcarbamate and 2-(methylamino)-2-oxoethyl 1-(4'-fluoro-1,1'-biphenyl-4-yl)cyclopropylmethylcarbamate; fatty acid amide (FAAH) hyrdrolase inhibitors; analgesics; neuropathic pain;psychological disorders; anticarcinogenic agents; AIDS |
| 01/19/2006 | US20060014827 3-(Cyclopenten-1-yl)-benzyl-or 3-(cyclopenten-1-yl)-heteroarylmethyl-amine derivatives and use thereof as medicines for treating schizophrenia |
| 01/19/2006 | US20060014822 1,2,4-Triaminobenzene derivatives useful for treating disorders of the central nervous system |
| 01/19/2006 | US20060014792 Heterocyclo inhibitors of potassium channel function |
| 01/19/2006 | US20060014789 Phenyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain or gastrointestinal disorders |
| 01/19/2006 | US20060014787 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| 01/19/2006 | US20060014781 Thiazole, imidazole and oxazole compounds and treatments of disorders associated with protein aging |
| 01/19/2006 | US20060014780 Nicotinamide derivatives useful as PDE4 inhibitors |
| 01/19/2006 | US20060014779 3-Aryloxy/thio-3-substituted propanamines and their use in inhibiting serotonin and norephinephrine reuptake |
| 01/19/2006 | US20060014775 Treatment of psychostimulant addiction |
| 01/19/2006 | US20060014762 2-Pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-A]pyrimidin-4-one and 7-pyridinyl-2,3-dihydoimidazo[1,2-A]pyrimidin-5(1H)one derivatives |
| 01/19/2006 | US20060014752 Heterocyclic anti-epileptogenic agents and methods of use thereof |
| 01/19/2006 | US20060014750 Pharmaceutical compositions for the treatment of CNS and other disorders |
| 01/19/2006 | US20060014747 Ortho-substituted anthranilic acid amides and their use as pharmaceutical agents |
| 01/19/2006 | US20060014746 Heteroaryl substituted fused bicyclic heteroaryl compounds as GABAA receptor ligands |
| 01/19/2006 | US20060014744 Midazopyrazinones and imidazotriazinones derivates as gaba-a receptor anxiolytic |
| 01/19/2006 | US20060014725 6-(1-benzyl-3-pentyl-1H-indol-2-yl)-1-bromo-2-naphthyl 1H-tetraazol-5-ylmethyl ether; useful in treating stroke associated with or resulting from atrial fibrillation; thrombolytic agents for prohylaxis of cardiovascular disorders |
| 01/19/2006 | US20060014701 Novel amide derivatives as growth hormone secretagogues |
| 01/19/2006 | US20060014665 Therapeutic agent |
| 01/19/2006 | US20060014242 Methods of modifying feeding behavior, compounds useful in such methods, and DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) |
| 01/19/2006 | US20060014216 Prophylaxis, therapy of Alzheimer's disease; using phenothiazine compound such as methylene blue |
| 01/19/2006 | US20060014180 Human phosphatase RET31, and variants thereof |
| 01/19/2006 | US20060013897 Compositions for cancer therapy saponins or sapogenins |
| 01/19/2006 | US20060013875 Combination immediate release controlled release levodopa/carbidopa dosage forms |
| 01/19/2006 | US20060013872 Pharmaceutical compositions comprising ibuprofen and domperidone |
| 01/19/2006 | US20060013869 Electrospun amorphous pharmaceutical compositions |
| 01/19/2006 | DE102004032103A1 Gegen Missbrauch gesicherte, orale Darreichungsform Abuse-proofed oral dosage form |
| 01/19/2006 | DE102004032051A1 Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform A process for preparing a secured against abuse, solid dosage form |
| 01/19/2006 | DE102004032049A1 Gegen Missbrauch gesicherte, orale Darreichungsform Abuse-proofed oral dosage form |
| 01/19/2006 | CA2574437A1 Infusion and injection solution of levodopa |
| 01/19/2006 | CA2573611A1 Agent for promoting the recovery from dysfunction after the onset of central neurological disease |
| 01/19/2006 | CA2573424A1 Method for preventing and treating alzheimer´s disease |
| 01/19/2006 | CA2573400A1 Cyclosporins to treat alzheimer's disease |
| 01/19/2006 | CA2573372A1 Sulfonamide derivatives |
| 01/19/2006 | CA2572982A1 Treatment of age-related memory impairment using phosphate-glycerol carrying bodies |
| 01/19/2006 | CA2570918A1 Use of phenylethanolaminotetralines for preparing anxiolytic drugs |
| 01/19/2006 | CA2570614A1 Sulfamate and sulfamide derivatives for the treatment of epilepsy and related disorders |
| 01/19/2006 | CA2570518A1 Tetracyclic compounds as estrogen ligands |
| 01/19/2006 | CA2570155A1 3-(heteroaryl-oxy)-2-alkyl-1-aza-bicycloalkyl derivatives as alpha.7-nachr ligands for the treatment of cns diseases |
| 01/19/2006 | CA2570096A1 Extended release formulation of 3-amino-8-(1-piperazinyl)-2h-1benzopyran-2-one |
| 01/18/2006 | EP1617218A1 METHOD OF SCREENING DRUG WITH THE USE OF 67 kDa LAMININ RECEPTOR AND DRUG OBTAINED THEREBY |
| 01/18/2006 | EP1617216A1 Novel method of screening |
| 01/18/2006 | EP1616878A1 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 01/18/2006 | EP1616862A1 Nitrogenous heterocyclic compound and use thereof |
| 01/18/2006 | EP1616577A1 Agent for repairing corneal perception |
| 01/18/2006 | EP1616576A1 Specific nad(p)h oxidase inhibitor |
| 01/18/2006 | EP1616565A1 Composition for relieving unpleasant symptoms accompanying change in protesterone |
| 01/18/2006 | EP1615936A1 Phosphates of secondary alcohols |
| 01/18/2006 | EP1615930A2 Triazolotriazines and pyrazolotriazines useful as a2a adenosine receptor antagonists |
| 01/18/2006 | EP1615929A1 Pyrrolo [1,2-b] pyridazine compounds and their uses |
| 01/18/2006 | EP1615925A1 Imidazopyridine derivatives as melanocortin receptor agonists |
| 01/18/2006 | EP1615924A1 Water soluble salts of risperidone |
| 01/18/2006 | EP1615923A1 Risperidone monohydrochloride |
| 01/18/2006 | EP1615922A1 Azaindole derivatives, preparations thereof, uses thereof and compositions containing them |
| 01/18/2006 | EP1615919A1 7-([1,4]dioxan-2-yl)-benzothiazole derivatives as adenosine receptor ligands |
| 01/18/2006 | EP1615915A1 Phenacyl 2-hydroxy-3-diaminoalkanes |
| 01/18/2006 | EP1615914A2 Cgrp receptor antagonists |
| 01/18/2006 | EP1615898A1 2-aminopyrimidine derivatives and their medical use |
| 01/18/2006 | EP1615896A1 Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds |
| 01/18/2006 | EP1615894A2 3-azabicyclo 3.2.1 octane derivatives |
| 01/18/2006 | EP1615893A1 2-azabicyclo[3.3.1]nonane derivatives as opioid receptor antagonists |
| 01/18/2006 | EP1615892A2 Benzamide 2-hydroxy-3-diaminoalkanes |
| 01/18/2006 | EP1615654A2 Nogo-receptor antagonists for the treatment of conditions involving amyloid plaques |
| 01/18/2006 | EP1615650A1 Phosphate derivatives of pharmaceutical products |
| 01/18/2006 | EP1615644A1 Substituted 4-phenyl-4-[1h-imidazol-2-yl]-piperidine derivatives and their use as selective non-peptide delta opioid agonists with antidepressant and anxiolytic activity |
| 01/18/2006 | EP1615643A1 4-phenyl-piperidine compounds and their use as modulators of opioid receptors |
| 01/18/2006 | EP1615642A1 Combination of paroxetine and 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)- (2s-phenyl-piperidin-3s-yl)-amine for treatment of depression and/or anxiety |
| 01/18/2006 | EP1615641A1 Combinations of paroxetine and 2-(r)-(4-fluoro-2-methyl-phenyl)-4-(s)-((8as)-6-oxo-hexahydro-pyrrolo 1,2-a -pyrazin-2-yl)-piperidine-1-carboxylic acid 1-(r)-(3,5-bis-trifluoromethyl-phenyl)-ethyl -methylamide for treatment of depression/anxiety |
| 01/18/2006 | EP1615636A1 Bicyclic compounds as nr2b receptor antagonists |
| 01/18/2006 | EP1615631A2 Use of l-dopa, derivatives thereof and medicaments comprising said compounds for the prophylaxis of psychotic diseases |
| 01/18/2006 | EP1615615A2 Pharmaceutical products |
| 01/18/2006 | EP1501505B1 Use of (3-(2-ethylphenyl)-5-methoxyphenyl)-1h- 1,2,4 -triazole for the treatment of autoimmune diseases |
| 01/18/2006 | EP1487427A4 Methods for preventing and treating peripheral neuropathy by administering desmethylselegiline |
| 01/18/2006 | EP1470138B1 Mmp inhibitors |
| 01/18/2006 | EP1463799A4 Methods for the induction of professional and cytokine-producing regulatory cells |
| 01/18/2006 | EP1435951B1 Phenyl substituted 5-membered nitrogen containing heterocycles for the tretment of obesity |
| 01/18/2006 | EP1412338B1 1,3,5-triazine-2,4,6-triones, preparation and use as gonadotropin-releasing hormone receptor antagonists |
| 01/18/2006 | EP1404672B1 Tyrosine kinase inhibitors |
| 01/18/2006 | EP1392309A4 Substituted pyrazinones, pyridines and pyrimidines as corticotropin releasing factor ligands |
| 01/18/2006 | EP1268096B1 Extrusion die |
| 01/18/2006 | EP1220852B1 Substituted diazepans |
| 01/18/2006 | EP1212335B1 Glucopyranosides conjugates of 2-(4-hydroxy-phenyl)-1- 4-(2-amin-1-yl-ethoxy)-benzyl]-1h-indol-5-ols |
| 01/18/2006 | EP1210327B1 New vitamin d derivatives with cyclic substructures in the side chains, method and intermediates for their production and their use in the preparation of medicaments |
| 01/18/2006 | EP1194410B1 Benzimidazole derivatives and pharmaceutical compositions comprising these compounds |
| 01/18/2006 | CN1723480A System and method for transparent early detection, warning, and intervention during a medical procedure |
| 01/18/2006 | CN1723211A Therapeutic agent for schizophrenia |
| 01/18/2006 | CN1723210A Fused furan compound |
| 01/18/2006 | CN1723205A Substituted benzoxazinones and uses thereof |
| 01/18/2006 | CN1723204A Benzoxazole derivatives and their use as adenosine receptor ligands |
| 01/18/2006 | CN1723201A Blood-brain barrier disruption inhibitors |
| 01/18/2006 | CN1723196A Fluoropyrrolidines as dipeptidyl peptidase inhibitors |
| 01/18/2006 | CN1723052A Enhanced parmacokinetic profile of hydrophobic dopamine agonists administered to the dermis |
| 01/18/2006 | CN1723026A Use of spongosine (2-methoxyadenosein) for the treatment of pain, in particular hyperalgesia |
| 01/18/2006 | CN1723021A Stable solid medicinal composition for oral administration. |
| 01/18/2006 | CN1723019A Compounds having anti-proliferative properties |